The investigational therapy uses SteadyTeq, a proprietary copolymer technology from Medincell designed to release olanzapine steadily over time
The Phase 2 study tested two dose levels of pumitamig alongside four standard chemotherapy regimens across first
Adverse events were similar to placebo, and no AP-101-induced antibody responses were detected
The study met its primary endpoint and all 11 secondary efficacy endpoints
It's a development that marks a potential breakthrough for people living with the rare and debilitating disease Duchenne muscular dystrophy (DMD)
Alport Syndrome is caused by genetic mutations affecting type IV collagen in the kidneys, ears, and eyes
Acromegaly, a rare chronic endocrine disorder caused by excess growth hormone, is seeing promising advances in treatment development
AEF0217 is a first-in-class CB1 receptor signaling-specific inhibitor
The company is excluding data from the affected sites to maintain the study's integrity
Suffering from acute migraine? You may soon bid adieu to the debilitating headache
Subscribe To Our Newsletter & Stay Updated
